Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis

Parental non‐alcoholic fatty liver disease increases risk of non‐alcoholic fatty liver disease in offspring

“…A twin study derived from a Southern California cohort showed that both hepatic steatosis and hepatic fibrosis are heritable traits with significant shared gene effects . A prospective study of probands with cirrhosis from non‐alcoholic steatohepatitis showed that both the odds of NAFLD and advanced fibrosis were significantly increased among the first‐degree relatives of patients with NASH cirrhosis compared to healthy controls . These data implicate the role of familial factors in increasing susceptibility towards NAFLD.…”

Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis

“…MRI‐PDFF was used to measure hepatic steatosis defined as MRI‐PDFF ≥ 5%. The details of the MRI protocol have been described previously . The median time between MRI‐PDFF and CAP was 8 days.…”

Link between gut‐microbiome derived metabolite and shared gene‐effects with hepatic steatosis and fibrosis in NAFLD

“…This was a cross sectional analysis of a prospective cohort study of patients from the Twin and Family Study (http://ClinicalTrials.gov:NCT01643512) residing in southern California. This study included a total of 156 participants, 100 twins (50 twin pairs) including 37 pairs of monozygotic (MZ), 13 pairs of dizygotic (DZ) and 56 participants either siblings or parents‐offspring recruited the University of California at San Diego (UCSD) NAFLD Research Center between December 2011 and January 2014. Please see Supporting Information for detailed visit research, inclusion and exclusion criteria.…”

“…The validation cohort included 156 participants prospectively recruited between October 2011 and May 2014 at the UCSD NAFLD Research Center . All patients with suspected NAFLD with a clinical indication for liver biopsy underwent a careful evaluation for other causes of hepatic steatosis and liver disease.…”